|
1
|
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.
|
Lancet
|
2004
|
7.78
|
|
2
|
Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients.
|
Int J Radiat Oncol Biol Phys
|
2009
|
6.11
|
|
3
|
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
|
J Clin Oncol
|
2008
|
5.11
|
|
4
|
A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database.
|
Int J Radiat Oncol Biol Phys
|
2007
|
5.07
|
|
5
|
Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.
|
J Clin Oncol
|
2009
|
4.59
|
|
6
|
Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases.
|
J Clin Oncol
|
2011
|
4.12
|
|
7
|
Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases.
|
J Clin Oncol
|
2009
|
3.00
|
|
8
|
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.
|
J Clin Oncol
|
2007
|
2.93
|
|
9
|
Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus.
|
Int J Radiat Oncol Biol Phys
|
2010
|
2.84
|
|
10
|
Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis.
|
J Clin Oncol
|
2010
|
2.71
|
|
11
|
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.
|
J Clin Oncol
|
2004
|
2.55
|
|
12
|
Patterns of surgical care of lung cancer patients.
|
Ann Thorac Surg
|
2005
|
2.51
|
|
13
|
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
|
J Thorac Oncol
|
2012
|
2.47
|
|
14
|
A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases.
|
Int J Radiat Oncol Biol Phys
|
2005
|
2.41
|
|
15
|
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
|
J Clin Oncol
|
2003
|
1.97
|
|
16
|
The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.
|
J Neurooncol
|
2009
|
1.96
|
|
17
|
Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.
|
Int J Radiat Oncol Biol Phys
|
2011
|
1.74
|
|
18
|
The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.
|
J Neurooncol
|
2009
|
1.70
|
|
19
|
National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care.
|
Lung Cancer
|
2007
|
1.64
|
|
20
|
Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214.
|
J Clin Oncol
|
2010
|
1.63
|
|
21
|
Interim analysis of a prospective phase I/II trial of SBRT for liver metastases.
|
Acta Oncol
|
2006
|
1.53
|
|
22
|
Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.47
|
|
23
|
Stereotactic radiosurgery (SRS) for brain metastases: a systematic review.
|
Radiat Oncol
|
2014
|
1.24
|
|
24
|
American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guidelines for image-guided radiation therapy (IGRT).
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.16
|
|
25
|
The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline.
|
J Neurooncol
|
2009
|
1.13
|
|
26
|
Update in the treatment of brain metastases from lung cancer.
|
Clin Lung Cancer
|
2006
|
1.11
|
|
27
|
American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT).
|
Int J Radiat Oncol Biol Phys
|
2009
|
1.08
|
|
28
|
The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline.
|
J Neurooncol
|
2009
|
1.07
|
|
29
|
Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504).
|
Clin Lung Cancer
|
2006
|
1.05
|
|
30
|
The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.
|
J Neurooncol
|
2009
|
1.04
|
|
31
|
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.
|
Lancet Oncol
|
2013
|
1.03
|
|
32
|
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.
|
Lancet Oncol
|
2013
|
1.03
|
|
33
|
Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.02
|
|
34
|
Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤ 6 brain metastases: a multi-institutional phase II trial.
|
J Neurooncol
|
2011
|
0.98
|
|
35
|
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.96
|
|
36
|
The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.
|
J Neurooncol
|
2013
|
0.94
|
|
37
|
Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.
|
J Clin Oncol
|
2009
|
0.92
|
|
38
|
Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review.
|
Radiat Oncol
|
2014
|
0.92
|
|
39
|
A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.92
|
|
40
|
American College of Radiology appropriateness criteria on multiple brain metastases.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.91
|
|
41
|
Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713.
|
J Clin Oncol
|
2004
|
0.90
|
|
42
|
Maximally safe resection followed by hypofractionated re-irradiation for locally recurrent ependymoma in children.
|
Pediatr Blood Cancer
|
2009
|
0.90
|
|
43
|
ACR Appropriateness Criteria: single brain metastasis.
|
Curr Probl Cancer
|
2010
|
0.89
|
|
44
|
Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy.
|
Pediatr Blood Cancer
|
2009
|
0.89
|
|
45
|
Chemoradiation for unresectable stage III non-small cell lung cancer.
|
Semin Thorac Cardiovasc Surg
|
2008
|
0.88
|
|
46
|
Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
|
J Neurooncol
|
2014
|
0.86
|
|
47
|
Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008.
|
Clin Cancer Res
|
2009
|
0.86
|
|
48
|
Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials.
|
Int J Radiat Oncol Biol Phys
|
2004
|
0.86
|
|
49
|
Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide.
|
J Neurooncol
|
2013
|
0.85
|
|
50
|
Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas.
|
Int J Radiat Oncol Biol Phys
|
2008
|
0.85
|
|
51
|
Dosimetric comparison between 3DCRT and IMRT using different multileaf collimators in the treatment of brain tumors.
|
Med Dosim
|
2009
|
0.83
|
|
52
|
Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
|
J Clin Oncol
|
2006
|
0.82
|
|
53
|
Resident-reported brachytherapy experience in ACGME-accredited radiation oncology training programs.
|
Brachytherapy
|
2013
|
0.82
|
|
54
|
A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer.
|
Front Oncol
|
2013
|
0.81
|
|
55
|
ACR Appropriateness Criteria® follow-up and retreatment of brain metastases.
|
Am J Clin Oncol
|
2012
|
0.80
|
|
56
|
The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.
|
J Neurooncol
|
2009
|
0.80
|
|
57
|
Retrospective clinicopathologic correlation of gross tumor size of hepatocellular carcinoma: implications for stereotactic body radiotherapy.
|
Am J Clin Oncol
|
2005
|
0.80
|
|
58
|
Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
|
J Neurooncol
|
2015
|
0.79
|
|
59
|
Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study.
|
Clin Cancer Res
|
2004
|
0.79
|
|
60
|
Prophylactic cranial irradiation for patients with lung cancer.
|
Clin Lung Cancer
|
2007
|
0.78
|
|
61
|
Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy.
|
Clin Lung Cancer
|
2005
|
0.78
|
|
62
|
The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline.
|
J Neurooncol
|
2009
|
0.78
|
|
63
|
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.78
|
|
64
|
Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.
|
J Thorac Oncol
|
2008
|
0.77
|
|
65
|
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.77
|
|
66
|
Cooperative group research endeavors in small-cell lung cancer: current and future directions.
|
Clin Lung Cancer
|
2009
|
0.77
|
|
67
|
Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer: Theory and Practice.
|
Cancer J
|
2015
|
0.77
|
|
68
|
Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2003.
|
Am J Clin Oncol
|
2003
|
0.76
|
|
69
|
Effect of induction chemotherapy on estimated risk of radiation pneumonitis in bulky non-small cell lung cancer.
|
Med Dosim
|
2013
|
0.76
|
|
70
|
Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources.
|
Int J Radiat Oncol Biol Phys
|
2006
|
0.75
|
|
71
|
Patient demographics in HOG LUN 01-24 versus SWOG 9504: apples versus oranges?
|
Clin Lung Cancer
|
2007
|
0.75
|
|
72
|
In regard to Yamamoto et al.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.75
|
|
73
|
Triple modality (neoadjuvant chemoradiotherapy followed by surgical resection): is it better than definitive chemoradiation therapy in cancer of the thoracic esophagus?
|
Int J Radiat Oncol Biol Phys
|
2002
|
0.75
|
|
74
|
Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer.
|
J Thorac Oncol
|
2011
|
0.75
|
|
75
|
Surprised by stage III: unexpected N2 lymph node involvement found during surgery for early-stage NSCLC.
|
Oncology (Williston Park)
|
2009
|
0.75
|
|
76
|
Stereotactic body radiation therapy for lung tumors: system-related issues and complications.
|
Clin Lung Cancer
|
2007
|
0.75
|
|
77
|
Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme.
|
J Med Imaging Radiat Oncol
|
2014
|
0.75
|